| 000 | 04284nam a2201225Ia 4500 | ||
|---|---|---|---|
| 000 | 02114ntm a2200205 i 4500 | ||
| 001 | 87683 | ||
| 003 | 0 | ||
| 005 | 20250920173727.0 | ||
| 008 | 230120n 000 0 eng d | ||
| 010 |
_z _z _o _a _b |
||
| 015 |
_22 _a |
||
| 016 |
_2 _2 _a _z |
||
| 020 |
_e _e _a _b _z _c _q _x |
||
| 022 |
_y _y _l _a2 |
||
| 024 |
_2 _2 _d _c _a _q |
||
| 028 |
_a _a _b |
||
| 029 |
_a _a _b |
||
| 032 |
_a _a _b |
||
| 035 |
_a _a _b _z _c _q |
||
| 037 |
_n _n _c _a _b |
||
| 040 |
_e _erda _a _d _b _c |
||
| 041 |
_e _e _a _b _g _h _r |
||
| 043 |
_a _a _b |
||
| 045 |
_b _b _a |
||
| 050 |
_a _a _d _b2 _c0 |
||
| 051 |
_c _c _a _b |
||
| 055 |
_a _a _b |
||
| 060 |
_a _a _b |
||
| 070 |
_a _a _b |
||
| 072 |
_2 _2 _d _a _x |
||
| 082 |
_a _a _d _b2 _c |
||
| 084 |
_2 _2 _a |
||
| 086 |
_2 _2 _a |
||
| 090 |
_a _a _m _b _q |
||
| 092 |
_f _f _a _b |
||
| 096 |
_a _a _b |
||
| 097 |
_a _a _b |
||
| 100 |
_e _e _aNikka Feb A. Adlaon. _d _b4 _u _c0 _q16 |
||
| 110 |
_e _e _a _d _b _n _c _k |
||
| 111 |
_a _a _d _b _n _c |
||
| 130 |
_s _s _a _p _f _l _k |
||
| 210 |
_a _a _b |
||
| 222 |
_a _a _b |
||
| 240 |
_s _s _a _m _g _n _f _l _o _p _k |
||
| 245 | 0 |
_a _aIn-silico screening and molecular docking study of selected flavonoids as a potential inhibitor against SARS-COV-2 3CLPRO / _d _b _n _cNikka Feb A. Adlaon. _h6 _p |
|
| 246 |
_a _a _b _n _i _f6 _p |
||
| 249 |
_i _i _a |
||
| 250 |
_6 _6 _a _b |
||
| 260 |
_e _e _a _b _f _c _g |
||
| 264 |
_3 _3 _a _d _b _cJune 2022.46 |
||
| 300 |
_e _e _c28 cm. _a101 pp. _b |
||
| 310 |
_a _a _b |
||
| 321 |
_a _a _b |
||
| 336 |
_b _atext _2rdacontent |
||
| 337 |
_3 _30 _b _aunmediated _2rdamedia |
||
| 338 |
_3 _30 _b _avolume _2rdacarrier |
||
| 340 |
_2 _20 _g _n |
||
| 344 |
_2 _2 _a0 _b |
||
| 347 |
_2 _2 _a0 |
||
| 362 |
_a _a _b |
||
| 385 |
_m _m _a2 |
||
| 410 |
_t _t _b _a _v |
||
| 440 |
_p _p _a _x _v |
||
| 490 |
_a _a _x _v |
||
| 500 |
_a _aThesis: (Bachelor of Science in Chemistry) - Pamantasan ng Lungsod ng Maynila, 2022. _d _b _c56 |
||
| 504 |
_a _a _x |
||
| 505 |
_a _a _b _t _g _r |
||
| 506 |
_a _a5 |
||
| 510 |
_a _a _x |
||
| 520 |
_b _b _c _aABSTRACT: The recent Covid-19 pandemic was caused by SARS-CoV-2, which impacted the entire world. In comparison to other enzymes, the major protease, 3CLpro (MPro), is a very desirable therapeutic target due to its capacity to cleave polyprotein. This study presents a molecular docking analysis of twenty-one representative flavonoids from each subclass against the 3CLpro, as well as the prediction of drug-likeness and ADMET characteristics. According to the docking analysis, each compound binds strongly to the amino acid residues present in the active site, including the catalytic dyad His41-Cys145 and Glu166. With the exception of Rutin and Epigallocatechin gallate, the drug-likeness prediction indicated agreement with Lipinski's criterion. In-silico ADMET property prediction further demonstrates that these representative flavonoids possed favourable solubility, adsorption, penetration, non-toxic, and non-carcinogenic properties comparable to the native ligand and FDA-approved drugs such as Remdesivir and Molnupiravir. The results of this investigation can be used to further optimize the representative flavonoids, as they have the potential to become effective inhibitors of SARS-CoV-2 3CLpro and exhibit the requisite ADMET characteristics to be considered therapeutic candidates. _u |
||
| 521 |
_a _a _b |
||
| 533 |
_e _e _a _d _b _n _c |
||
| 540 |
_c _c _a5 |
||
| 542 |
_g _g _f |
||
| 546 |
_a _a _b |
||
| 583 |
_5 _5 _k _c _a _b |
||
| 590 |
_a _a _b |
||
| 600 |
_b _b _v _t _c2 _q _a _x0 _z _d _y |
||
| 610 |
_b _b _v _t2 _x _a _k0 _p _z _d6 _y |
||
| 611 |
_a _a _d _n2 _c0 _v |
||
| 630 |
_x _x _a _d _p20 _v |
||
| 648 |
_2 _2 _a |
||
| 650 |
_x _x _a _d _b _z _y20 _v |
||
| 651 |
_x _x _a _y20 _v _z |
||
| 655 |
_0 _0 _a _y2 _z |
||
| 700 |
_i _i _t _c _b _s1 _q _f _k40 _p _d _e _a _l _n6 |
||
| 710 |
_b _b _t _c _e _f _k40 _p _d5 _l _n6 _a |
||
| 711 |
_a _a _d _b _n _t _c |
||
| 730 |
_s _s _a _d _n _p _f _l _k |
||
| 740 |
_e _e _a _d _b _n _c6 |
||
| 753 |
_c _c _a |
||
| 767 |
_t _t _w |
||
| 770 |
_t _t _w _x |
||
| 773 |
_a _a _d _g _m _t _b _v _i _p |
||
| 775 |
_t _t _w _x |
||
| 776 |
_s _s _a _d _b _z _i _t _x _h _c _w |
||
| 780 |
_x _x _a _g _t _w |
||
| 785 |
_t _t _w _a _x |
||
| 787 |
_x _x _d _g _i _t _w |
||
| 800 |
_a _a _d _l _f _t0 _q _v |
||
| 810 |
_a _a _b _f _t _q _v |
||
| 830 |
_x _x _a _p _n _l0 _v |
||
| 942 |
_a _alcc _cBK |
||
| 999 |
_c25437 _d25437 |
||